Admera Liquid Biopsy Testing

Admera Health has announced the imminent launch of its liquid biopsy cancer test using the company's proprietary BEST blocker enrichment technology. The test involved identify the BRAF V600 tumor mutation frequently found in melanoma and also observed in non-small cell lung cancer, colorectal cancer, papillary thyroid cancer, ovarian cancer, glioma, and gastrointestinal stromal tumor. The BEST technology can reliably isolate and amplify circulating cell-free tumor DNA fragments in the bloodstream and then identify actionable genetic mutations, using next generation sequencing technology and advanced bioinformatics analysis systems. The test will be run through the company's New Jersey-based, CLIA approved laboratory.